锂相关急慢性肾毒性的诊断与管理
本文综述锂相关肾毒性的发病机制与临床管理框架。锂经钠转运途径在细胞内蓄积,通过线粒体功能障碍和氧化应激导致损伤,呈剂量依赖性肾毒性。急性血锂升高可因锂致钠尿和水利尿引起严重容量不足及AKI;慢性使用最常见并发症为精氨酸升压素抵抗,CKD多在10年以上潜伏期后出现,进展至肾衰竭比例相对较低。使用最低有效剂量、密切监测肾功能和血锂水平、早期诊断是关键。
要点
- 锂经钠转运途径在细胞内蓄积,通过线粒体功能障碍和氧化应激导致剂量依赖性肾毒性。
- 慢性锂使用最常见并发症为精氨酸升压素抵抗,可早期出现;CKD潜伏期超过10年。
- 阿米洛利等上皮钠通道阻滞剂可减少细胞蓄积,有助于减轻锂肾毒性。
核心结论
- 使用最低有效锂剂量、密切监测肾功能和血锂水平并早期诊断锂肾毒性,对预防不可逆肾损伤至关重要。
- 停用锂的决策具有挑战性,须仔细权衡获益与风险。
研究设计与样本
- 本文为综合性综述,提供锂肾毒性的发病机制基础及诊断与管理的实用临床框架。
主要发现
- 锂经钠转运途径在细胞内蓄积,抑制糖原合成酶激酶-3β等复杂细胞信号机制,细胞内水平升高通过线粒体功能障碍和氧化应激触发损伤。
- 锂治疗指数窄,引起剂量依赖性肾毒性,典型为肾小管间质损伤模式,但也可罕见引起肾小球损伤。
- 急性血锂升高可因锂致钠尿和水利尿导致严重容量不足并引起AKI;肾功能变化和多种药物相互作用可急性影响血锂水平。
- 慢性锂使用最常见并发症为精氨酸升压素抵抗,可为早期表现;CKD在超过10年的较长潜伏期后发生,GFR下降斜率可变,进展至肾衰竭相对较低但受其他肾毒性危险因素影响。
- 锂致甲状旁腺功能亢进引起的高钙血症与肾结石和CKD进展风险升高相关;锂致CKD常见肾脏微囊性改变,也可见远端肾小管酸中毒。
关键数值与推荐
- 上皮钠通道阻滞剂如阿米洛利可通过减少细胞蓄积帮助减轻锂肾毒性。
- 使用最低有效锂剂量并密切监测肾功能和血锂水平。
临床怎么用
- 对锂治疗患者应密切监测肾功能和血锂水平,警惕急性血锂升高及药物相互作用对血锂的影响。
- 识别精氨酸升压素抵抗等早期表现,并在慢性使用超过10年者中关注CKD发生。
- 可考虑阿米洛利减少锂的细胞蓄积以减轻肾毒性;停药须权衡获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lithium remains a mainstay of therapy for bipolar disease and refractory depression, with future potential for expanded use on the basis of novel data demonstrating its immunomodulatory and neuroprotective effects. This drug accumulates intracellularly via sodium transport pathways, and its effects on complex cellular signaling mechanisms, including glycogen synthase kinase-3 β inhibition, form the basis of its therapeutic efficacy and toxicity. Increased intracellular levels disrupt cellular processes and trigger injury via mitochondrial dysfunction and oxidative stress. Lithium has a narrow therapeutic index and causes dose-dependent nephrotoxicity. A tubulointerstitial pattern of kidney injury is typical; however, lithium can rarely cause glomerular injury as well. An acute rise in serum lithium levels can result in severe volume depletion from lithium-induced natriuresis and aquaresis and cause AKI. Changes in kidney function and various drug interactions can acutely affect serum lithium levels, further increasing the risk of toxicity. Arginine vasopressin resistance is the most common complication of chronic lithium use and can be an early manifestation. CKD occurs after a longer latency of over 10 years with a variable slope of GFR decline. Progression to kidney failure is relatively low but is affected by the presence of other nephrotoxic risk factors. Epithelial sodium channel blockers such as amiloride can be helpful in mitigating lithium nephrotoxicity by reducing cellular accumulation. Hypercalcemia secondary to lithium-induced hyperparathyroidism is associated with a higher risk of nephrolithiasis and CKD progression. Kidney microcystic changes are common in lithium-induced CKD, and distal renal tubular acidosis can also be seen. Using the lowest effective lithium dose, close monitoring of kidney function and serum lithium levels and early diagnosis of lithium nephrotoxicity is critical in preventing irreversible kidney injury. The decision to discontinue lithium is challenging, and the benefits versus risks must be carefully weighed. This comprehensive review provides a pathogenetic basis and practical clinical framework for diagnosis and management of lithium nephrotoxicity.
引用
- Krishnan N, Perazella MA. Diagnosis and Management of Acute and Chronic Lithium-Associated Nephrotoxicity. J Am Soc Nephrol. 2026. PMID: 42247265. doi:10.1681/ASN.0000001172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。